- Home
- EVM vs TLSI Comparison
EVM vs TLSI Comparison
Compare EVM & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- TLSI
- Stock Information
- Founded
- EVM 2002
- TLSI 2010
- Country
- EVM United States
- TLSI United States
- Employees
- EVM N/A
- TLSI N/A
- Industry
- EVM Finance/Investors Services
- TLSI Medical Specialities
- Sector
- EVM Finance
- TLSI Health Care
- Exchange
- EVM Nasdaq
- TLSI Nasdaq
- Market Cap
- EVM 235.5M
- TLSI 244.3M
- IPO Year
- EVM N/A
- TLSI N/A
- Fundamental
- Price
- EVM $9.55
- TLSI $4.85
- Analyst Decision
- EVM
- TLSI Strong Buy
- Analyst Count
- EVM 0
- TLSI 4
- Target Price
- EVM N/A
- TLSI $11.13
- AVG Volume (30 Days)
- EVM 55.8K
- TLSI 129.6K
- Earning Date
- EVM 01-01-0001
- TLSI 11-13-2025
- Dividend Yield
- EVM 4.01%
- TLSI N/A
- EPS Growth
- EVM N/A
- TLSI N/A
- EPS
- EVM 0.20
- TLSI N/A
- Revenue
- EVM N/A
- TLSI $35,990,000.00
- Revenue This Year
- EVM N/A
- TLSI $56.79
- Revenue Next Year
- EVM N/A
- TLSI $54.15
- P/E Ratio
- EVM $47.61
- TLSI N/A
- Revenue Growth
- EVM N/A
- TLSI 45.50
- 52 Week Low
- EVM $7.67
- TLSI $3.42
- 52 Week High
- EVM $9.59
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- EVM 67.29
- TLSI 46.62
- Support Level
- EVM $9.53
- TLSI $4.42
- Resistance Level
- EVM $9.74
- TLSI $4.67
- Average True Range (ATR)
- EVM 0.07
- TLSI 0.23
- MACD
- EVM -0.01
- TLSI -0.02
- Stochastic Oscillator
- EVM 37.59
- TLSI 57.15
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.